Canntab Therapeutics Limited Stock price Deutsche Boerse AG

Equities

TBF1

CA1377991023

Pharmaceuticals

Delayed Deutsche Boerse AG 02:00:59 2023-10-05 am EDT 5-day change 1st Jan Change
0.0005 EUR -.--% Intraday chart for Canntab Therapeutics Limited -.--% -.--%
Sales 2021 - Sales 2022 0.29 0.27 Capitalization 11.48M 10.64M
Net income 2021 -4M -3.71M Net income 2022 -3M -2.78M EV / Sales 2021 -
Net Debt 2021 75.05K 69.57K Net Debt 2022 1.15M 1.07M EV / Sales 2022 43,043,762 x
P/E ratio 2021
-7.9 x
P/E ratio 2022
-3.02 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 86.26%
More Fundamentals * Assessed data
Dynamic Chart
Canntab Therapeutics Limited Provide an Update on Product Delivery CI
Canntab Therapeutics Limited Reports Earnings Results for the Third Quarter and Nine Months Ended February 28, 2023 CI
Canntab Therapeutics Limited Reports Earnings Results for the Second Quarter and Six Months Ended November 30, 2022 CI
Canntab Therapeutics Limited Reports Earnings Results for the First Quarter Ended August 31, 2022 CI
Canntab Therapeutics Limited Auditor Raises 'Going Concern' Doubt CI
Canntab Therapeutics Limited Reports Earnings Results for the Full Year Ended May 31, 2022 CI
Canntab Therapeutics on Entrance Into the Nova Scotia Cannabis Market MT
Canntab Therapeutics Limited Announces Chief Executive Office Changes CI
Canntab Therapeutics Limited Reports Earnings Results for the Third Quarter and Nine Months Ended February 28, 2022 CI
Canntab Therapeutics Limited Receives Approval from the Province of Saskatchewan to Begin Sales CI
Canntab Therapeutics Limited Enters into Affiliate Agreement with Onpharm-United CI
Canntab Therapeutics Limited Signs Historic Agreement with First Nations Growers Gp Inc. to Address the Opiate and Illicit Drug Crisis Affecting Indigenous Peoples Throughout Canada CI
Canntab Therapeutics Limited announced that it has received CAD 1.312 million in funding CI
Canntab Therapeutics Limited Reports Earnings Results for the Second Quarter and Six Months Ended November 30, 2021 CI
Canntab Therapeutics Limited Officially Launches its Online E-Commerce Platform CI
More news
1 year
0.00
Extreme 0.0005
0.02
3 years
0.00
Extreme 0.0005
0.72
5 years
0.00
Extreme 0.0005
0.73
10 years
0.00
Extreme 0.0005
1.37
More quotes
Managers TitleAgeSince
Chief Executive Officer 63 16-04-19
President 56 16-04-19
Chief Tech/Sci/R&D Officer - 20-05-14
Members of the board TitleAgeSince
President 56 16-04-19
Director/Board Member 61 18-04-10
Director/Board Member 71 18-04-10
More insiders
Canntab Therapeutics Limited is a Canadian phytopharmaceutical company focused on the manufacturing and distribution of a suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations. The Company’s operations comprise a single segment engaged in the medical marijuana business. The Company’s hard pill cannabinoid formulations provide doctors, patients, and consumers with medical grade solutions. These include once a day and extended-release formulations. Its products include INSTANT RELEASE - (IR Tablet), EXTENDED-RELEASE - (XR Tablet), and ORAL DISSOLVING - O.D. Tablet (ODT). The IR Tablet is a release profile for solid hard tablets. The XR Tablet is a phytocannabinoid vehicle that is designed to directly address the drawbacks and challenges of competing oral delivery systems. ODT is specifically designed to dissolve directly in the patient’s mouth, with an onset of action between five and thirty minutes.
More about the company
  1. Stock
  2. Equities
  3. Stock Canntab Therapeutics Limited
  4. Stock Canntab Therapeutics Limited - Deutsche Boerse AG